General
Preferred name
FAVIPIRAVIR
Synonyms
6-Fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide ()
T-705 ()
T-705 (Favipiravir) ()
T705-18 ()
Avigan ()
Favipiravir (T-705) ()
P&D ID
PD021515
CAS
259793-96-9
Tags
available
prodrug
drug
Approved by
PMDA
First approval
2014
Drug Status
investigational
approved
Drug indication
Coronavirus Disease 2019 (COVID-19)
Influenza virus infection
Max Phase
Phase 3
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCPRITION A pyrazinecarboxamide derivative with activity against RNA viruses. Favipiravir is converted to the ribofuranosyltriphosphate derivative by host enzymes and selectively inhibits the influenza viral RNA-dependent RNA polymerase.
DESCRIPTION Favipiravir (T-705) is an orally delivered, guanine (purine) analogue antiviral drug (cf. which is administered i.v.). It targets viral RNA-dependent RNA polymerase (RdRP) of RNA viruses and since the catalytic domain of RdRP is well conserved across species, has a broad-spectrum of activity; although Furuta et al. (2002) reported that actvity was weak against non-influenza virus RNA viruses . Favipiravir was originally identified through a chemical library screen against influenza virus RdRP . Chemically, it is a prodrug. In human cells it undergoes phosphoribosylation and phosphorylation to its active form, favipiravir-ribofuranosyl-5′-triphosphate (F-RTP). F-RTP is bound by the RdRP, but it blocks enzyme activity and so terminates chain elongation . (GtoPdb)
DESCRIPTION Viral RNA-dependent RNA polymerase (RdRP) inhibitor; broad spectrum antiviral nucelotide prodrug (Tocris Bioactive Compound Library)
Cell lines
0
Organisms
15
Compound Sets
16
AdooQ Bioactive Compound Library
A11590
Axon Medchem Screening Library
3135
Cayman Chemical Bioactives
23384
ChEMBL Drugs
CHEMBL221722
Drug Repurposing Hub
DrugBank
DB12466
DrugBank Approved Drugs
DB12466
DrugCentral
4887
DrugCentral Approved Drugs
4887
DrugMAP
DMBZ27L
DM35GBS
Guide to Pharmacology
11139
MedChem Express Bioactive Compound Library
HY-14768
ReFrame library
Selleckchem Bioactive Compound Library
favipiravir-t-705
TargetMol Bioactive Compound Library
T6833
Tocris Bioactive Compound Library
7225
External IDs
31
Properties
(calculated by RDKit )
Molecular Weight
157.03
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
1
Ring Count
1
Aromatic Ring Count
1
cLogP
-0.58
TPSA
89.1
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.57
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
RNA-dependent RNA polymerase
RNAP inhibitor
Bacterial
DNA/RNA Synthesis
Influenza Virus
SARS-CoV
COVID-19,DNA/RNA Synthesis,Influenza Virus
Primary Target
RNA Polymerase
MOA
Inhibitor
RNA polymerase inhibitor
Therapeutic Class
Antiviral Agents
Pathway
Anti-infection
Cell Cycle/DNA Damage
Source data